Clinical trials: Genital Neoplasm, Female
Cervical Cancer
Testing an Implementation Science Tool to Increase Cervical Cancer Screening in Mombasa, Kenya
Cervical cancer is the most common cancer in women in sub-Saharan Africa, and the majority of cervical cancer mortality occur in low and middle income countries (LMICs).
- Trial name
- NCT03514459
- Testing
- Systems Analysis and Improvement Approach
- Where
- Kenya
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Washington
Infections, Papillomavirus, Papillomavirus Vaccines
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This Phase IV, observer-blind study is designed to evaluate the safety and immunogenicity of Cervarix in HIV infected…
- Trial name
- NCT01031069
- Testing
- GSK Biologicals' HPV vaccine 580299, Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)
- Where
- 15 sites in Brazil, Estonia and 2 more
- Volunteers
- 873 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ovarian Cancer
Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian Cancer
This research study will test whether using wearable fitness trackers with a social incentive, delivered through a game-based mobile health intervention, increases physical activity and quality of life in ovarian cancer survivors.
- Trial name
- NCT03364673
- Testing
- Fitness Tracker, Social Incentive (Way to Health)
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Infections, Papillomavirus
Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women
Human papillomavirus infection has clearly been recognized as the cause of cervical cancer. Indeed, the infection of the cervix by certain oncogenic types of HPV, if not cleared , can lead over time to cervical cancer in women .
- Trial name
- NCT00344032
- Testing
- HPV-16/18 VLP/AS04 Vaccine (Cervarix TM)
- Where
- 4 sites in India
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancers, Vulvar Cancer
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
This study will evaluate the immunogenicity and tolerability of V503 (a multivalent human papillomavirus [HPV] L1 virus-like particle [VLP] vaccine) in preadolescent and adolescent participants between 9 and 15 years old and…
- Conditions
- Cervical Cancers, Vulvar Cancer, Vaginal Cancer, Genital Lesions
- Trial name
- NCT00943722
- Testing
- V503
- Volunteers
- 3,074 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Polycystic Ovary Syndrome
Effect of Increased Circulating Androgens on Granulosa Cell Responses to FSH.
The purpose of this study is to evaluate the effect of increased circulating androgens on estradiol production by the granulosa cells in response to FSH stimulus.
- Trial name
- NCT02389088
- Testing
- Letrozole
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Papillomavirus Infections
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
The purpose of this study is to evaluate the safety and tolerability of the Quadrivalent Human Papilloma Virus (HPV) vaccine in healthy females 9 to 15 years of age in India.
- Trial name
- NCT00380367
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancers, Vulvar Cancers
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
This study will evaluate whether V503 (9vHPV vaccine), is well tolerated in girls and women between 12 and 26 years old who have previously been vaccinated with GARDASIL™.
- Conditions
- Cervical Cancers, Vulvar Cancers, Vaginal Cancers, Genital Warts
- Trial name
- NCT01047345
- Testing
- V503
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV Infections
V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)
The study evaluates the immunogenicity, safety and tolerability of V501 in preadolescent females
- Trial name
- NCT00411749
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer, Anal Cancer
A Chatbot Intervention for Reducing HPV Vaccine Hesitancy
The goal of this project is to test the efficacy of a chatbot intervention for reducing HPV vaccine hesitancy among African American parents.
- Conditions
- Cervical Cancer, Anal Cancer, Penile Cancer
- Trial name
- NCT05959564
- Testing
- Personalized Chatbot Intervention, Non-Personalized Chatbot Intervention, No Chatbot Control
- Where
- United States
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- University of Maryland, College Park
Polycystic Ovary Syndrome (PCOS)
Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women
The purpose of this research study is to collect specimen samples and study medical information from women with Polycystic Ovary Syndrome (PCOS) and women without PCOS.
- Trial name
- NCT01889199
- Testing
- Flutamide
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Urinary Incontinence
Conservative Treatment of Postprostatectomy Incontinence
The primary purpose of this study is to test the effectiveness, impact on quality of life, and durability of non-surgical therapies for incontinence persisting at least one year after surgery.
- Trial name
- NCT00212264
- Testing
- Behavioral Therapy, Pelvic Floor Electrical Stimulation, Biofeedback
- Where
- United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Polycystic Ovarian Syndrome, Obesity
Post-Prandial Liver Glucose Metabolism in PCOS
The Investigators will measure if hepatic metabolism is upregulated in obese girls with PCOS and hepatic steatosis (HS), compared to PCOS without HS and obese controls without HS.
- Conditions
- Polycystic Ovarian Syndrome, Obesity, Hepatic Steatosis
- Trial name
- PLUM (NCT03041129)
- Testing
- oral glucose tolerance test, MRI of liver
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Cervical Cancer
Cervical Cancer Prevention for Black Adults
The goal of this study is to develop and pilot test an intervention, entitled Health is Wealth: A Cervical Health Program, designed to promote screening and reduce perceived barriers to Cervical Cancer (CC) screening.
- Trial name
- NCT04927494
- Testing
- Health is Wealth: A Cervical Health Program
- Where
- United States
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- Adebola Adegboyega
Polycystic Ovary Syndrome
Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women
The goal of this three-armed randomized controlled trial is to establish the relative roles of treatment of hyperandrogenism versus obesity (as the largest modifiable factor contributing to insulin resistance) in treating…
- Trial name
- OWL-PCOS (NCT00704912)
- Testing
- Orlistat/Meal Replacement/Lifestyle Modification, Loestrin 1/20, Combination of treatments
- Where
- 2 sites in United States
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Cervical Cancer, Cervical Precancerous Lesions
Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India
The primary study hypothesis wasthat a two-dose human papillomavirus (HPV) vaccine regimen would offer similar immunogenicity and protection as that of a three-dose regimen to girls against persistent HPV infection and cervical…
- Trial name
- NCT00923702
- Testing
- Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)
- Where
- 8 sites in India
- Volunteers
- 22,729 people, healthy volunteers welcome
- Sponsor
- Partha Basu
Polycystic Ovary Syndrome, c Type Natriuretic Peptide
Comparison of Serum C Type Natriuretic Peptide Levels Between Polycystic Ovary Syndrome Patients and Healthy Women
Recent studies have shown that C natriuretic peptide is produced from granulosa cells, increasing cumulative guanosine monophosphate (cGMP) production by affecting cumulus cells through natriuretic peptide receptors.
- Conditions
- Polycystic Ovary Syndrome, c Type Natriuretic Peptide, Menstrual Irregularity, Hyperandrogenism
- Trial name
- CNP (NCT04006171)
- Testing
- C type natriuretic peptide
- Where
- Cyprus
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Near East University, Turkey
Infections, Papillomavirus
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00196937
- Testing
- Cervarix
- Where
- 6 sites in Germany, Poland
- Volunteers
- 667 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Papillomavirus, Papillomavirus Vaccines
Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.
Human papillomavirus infection has clearly been recognized as the cause of cervical cancer. Indeed, the infection of the cervix by certain oncogenic types of HPV, if not cleared , can lead over time to cervical cancer in women .
- Trial name
- NCT00250276
- Testing
- Cervarix™
- Where
- 8 sites in Denmark, Lithuania and 1 more
- Volunteers
- 798 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Polycystic Ovary Syndrome
Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study
The purpose is to investigate the effects of 2 different treatments (drospirenone/ethinyl estradiol versus rosiglitazone) on insulin sensitivity and androgen levels, inflammatory markers, vascular markers and bone development in…
- Trial name
- NCT00640224
- Testing
- rosiglitazone, drospirenone/ethinyl estradiol
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Silva Arslanian